ERBB2 and breast cancer: CAR-NK cell-derived exosomes and transferrin receptor binding peptide (T7) constitute a nanoplatform capable of crossing the blood-brain barrier. This nanoplatform selectively exerts antitumor effects on HER2-positive breast cancer cells in the brain through CAR on the exosomal surface.